Send the following on WhatsApp
Continue to Chat弊大於利、證據不足!美腫藥物瘤諮詢委員會(ODAC)接連否決兩家癌藥核准 https://geneonline.news/oncopeptides-spectrum-fda-odac/?variant=zh-cn
弊大於利、證據不足!美腫藥物瘤諮詢委員會(ODAC)接連否決兩家癌藥核准 https://geneonline.news/oncopeptides-spectrum-fda-odac/?variant=zh-cn